Brief Article Open Access
Copyright ©2012 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Oct 14, 2012; 18(38): 5427-5433
Published online Oct 14, 2012. doi: 10.3748/wjg.v18.i38.5427
Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: Case series analysis
Jui-Ho Wang, Tai-Ming King, Min-Chi Chang, Chao-Wen Hsu, Division of Colorectal Surgery, Department of Surgery, Kaohsiung Veteran General Hospital, Kaohsiung 81346, Taiwan, China
Chao-Wen Hsu, Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan, China
Author contributions: Hsu CW wrote the manuscript and Wang JH revised the manuscript; King TM, Chang MC collected the data on the cases.
Correspondence to: Dr. Chao-Wen Hsu, Division of Colorectal Surgery, Department of Surgery, Kaohsiung Veteran General Hospital, Kaohsiung 81346, Taiwan, China. ss851124@gmail.com
Telephone: +886-7-3422121 Fax: +886-7-3422121
Received: March 3, 2012
Revised: June 20, 2012
Accepted: July 9, 2012
Published online: October 14, 2012

Abstract

AIM: To investigate oxaliplatin-induced severe anaphylactic reactions (SAR) in metastatic colorectal cancer in a retrospective case series analysis and to conduct a systemic literature review.

METHODS: During a 6-year period from 2006 to 2011 at Kaohsiung Veterans General Hospital, a total of 412 patients exposed to oxaliplatin-related chemotherapy were retrospectively reviewed. Relevant English-language studies regarding life-threatening SAR following oxaliplatin were also reviewed in MEDLINE® and PubMed® search.

RESULTS: Eight patients (1.9%, 8 of 412 cases) were identified. Seven patients were successful resuscitated without any sequelae and one patient expired. We changed the chemotherapy regimen in five patients and rechallenged oxaliplatin use in patient 3. Twenty-three relevant English-language studies with 66 patients were reported. Patients received a median of 10 cycles of oxaliplatin (range, 2 to 29). Most common symptoms were respiratory distress (60%), fever (55%), and hypotension (54%). Three fatal events were reported (4.5%). Eleven patients (16%) of the 66 cases were rechallenged by oxaliplatin.

CONCLUSION: SAR must be considered in patients receiving oxaliplatin-related chemotherapy, especially in heavily pretreated patients. Further studies on the mechanism, predictors, preventive methods and management of oxaliplatin-related SAR are recommended.

Key Words: Oxaliplatin, Anaphylactic, Colorectal cancer, Metastasis



INTRODUCTION

Colorectal cancer (CRC) accounts for 10% to 15% of all cancers and is the third leading cause of cancer deaths in Taiwan. Oxaliplatin is a third generation platinum compound frequently used in the treatment of stage III CRC as adjuvant chemotherapy[1] and stage IV advanced CRC[2]. Similar to other platinum compounds, oxaliplatin interacts with DNA to form intra-strand/inter-strand DNA cross-linking that can affect DNA base pairing, replication, and gene transcription and cause cell death[3]. Among the common reasons for its withdrawal are frequent peripheral neuropathy, a delayed hypersensitivity reaction, and most troublesome, anaphylaxis when patients receive accumulated doses of oxaliplatin[4]. Hypersensitivity reaction and anaphylaxis refers to undesirable reactions produced by the normal immune system, including allergies and autoimmunity. These reactions may be damaging, uncomfortable, or occasionally fatal.

Multiple mechanisms of action have been proposed including the use of various neuroprotective agents in the hope of achieving adequate oxaliplatin doses with less neuropathy[5]. Much less is known about acute reactions such as anaphylaxis, and it is generally considered to be associated with immune-mediated effects[6,7]. The percentage of hypersensitivity reactions quoted in different studies ranges from 8% to 20%, but is usually around 10% to 12%[8]. Life-threatening severe anaphylactic reactions (SAR) have been reported but no systemic review of their incidence has been undertaken. Therefore, we performed a retrospective analysis of our patients who had been exposed to oxaliplatin and selected those who developed SAR requiring hospitalization with medical intervention. We also conducted a systemic literature review on this issue.

MATERIALS AND METHODS
Chart review

During a 6-year period from 2006 to 2011 at Kaohsiung Veterans General Hospital, a total of 412 patients exposed to oxaliplatin-related chemotherapy were retrospectively reviewed. Life-threatening SAR was defined as side effects including symptomatic bronchospasm, allergy-related edema/angioedema, hypotension or anaphylaxis (grade III/IV anaphylactic reactions reference by NIH common Toxicity Criteria v3.0) requiring hospitalization and medical interventions[9]. The oxaliplatin-related chemotherapy regimen (FOLFOX) consisted of leucovorin 200 mg/m2 as a 2-h infusion, and oxaliplatin 85 mg/m2 given as a 2-h infusion in 500 mL of dextrose 5% via a Y-connector, followed by a 46-h infusion of 5-fluorouracil 2500 mg/m2, repeated every 2 wk. Anti-emetic prophylaxis with a 5HT3-receptor antagonist was administered. The use of implantable ports and disposable or electronic pumps allowed chemotherapy to be administered on an inpatient basis.

Data collection and literature review

Information collected included age, sex, allergy history, primary CRC site, tumor, nodes, metastasis classification, CRC stage, previous chemotherapy regimens, previous oxaliplatin-related chemotherapy cycles, oxaliplatin dosage, tumor response, onset time after oxaliplatin infusion, and outcome. Relevant English-language studies regarding life-threatening SAR following oxaliplatin were also reviewed. We searched the relevant studies by entering keywords “severe side effect after oxaliplatin”, “life-threatening reaction after oxaliplatin” and “severe anaphylactic reaction after oxaliplatin” in MEDLINE® and PubMed® searches.

RESULTS
Patient characteristics

Eight patients (1.9%, 8 of 412 cases) were identified who developed life-threatening SAR, which occurred after infusion of oxaliplatin-related chemotherapy. The patients’ characteristics were described in Table 1. There were 4 females and patients’ age ranged from 36 to 72 years. Three patients had rectal cancer, 4 patients had sigmoid colon cancer, and 1 patient had descending colon cancer. Two patients had an allergy history to alcohol and flurbiprofen respectively. All patients had stage IV metastatic disease and received several lines of different chemotherapy regimens. Patients had received 5-29 cycles of oxaliplatin-related chemotherapy. Oxaliplatin dosages were 85 mg/m2 in six patients and 90 mg/m2 in one patient. Stable disease was achieved in three patients and progressive disease in five patients. Onset time after oxaliplatin infusion ranged from immediate to two hours. Seven patients were successfully resuscitated with oxygen support and medical interventions and fully recovered without any sequelae. However, one patient suffered from SAR and shock status 20 min after infusion of oxaliplatin. Despite cardiopulmonary resuscitation and use of inotropic agents, this patient expired 50 min later. We changed the chemotherapy regimen in five patients and rechallenged oxaliplatin use in patient 3. Because the patient 3’s disease manifestations responded well to FOLFOX chemotherapy regimen, continuation was felt to be desirable. We have thus decided to attempt rechallenge of oxaliplatin by prolonging the infusion rate and using premedication with an additional 100 mg hydrocortisone plus diphenhydramine before the next treatment course. Fortunately, no anaphylactic reactions developed thereafter.

Table 1 Clinical characteristics of patients with life-threatening severe anaphylactic reactions following oxaliplatin chemotherapy (n = 8).
PatientSexAge (yr)Allergy historyPrimary CRC siteTNM classificationStagePrevious chemotherapy regimensPrevious oxaliplatin chemotherapy cyclesOxaliplatin dose (mg/m2)Tumor responsePresenting symptomsOnset timeOutcomeRechallenge
1F50AlcoholRectumT4N0M1IVFOLFIRI x12, FOLFOX x101085SDConsciousness loss, dizziness, shock30 minRecoveryNo
2M71NilRectumT2N1M1IVFOLFOX x12, FOLFIRI + Bevacizumabx12, FOLFOX x11385PDConsciousness loss, shock20 minFatalNo
3M36NilSigmoid colonT4N2M1IVFOLFIRI x13, FOLFOX + Bevacizumab x5, FOLFIRI + Cetuximab x5, FOLFOX x71290PDConsciousness loss, respiratory distress, cold sweatingImmediateRecoveryYes
4F57NilSigmoid colonT1N0M1IVFOLFIRI x5, FOLFOX x7, FOLFIRI + Bevacizumabx18, FOLFOX + Bevacizumab x1885PDRespiratory distress, cold sweating2 hRecoveryNo
5F68NilSigmoid colonT3N2M1IVFOLFIRI x12, FOLFOX x8885SDAngioedema, slurred speech, respiratory distress30 mRecoveryNo
6F72NilDescending colonT4N1M1IVFOLFIRI x7, FOLFOX x3, FOLFIRI x12, FOLFOX x2585PDNausea, vomiting, shock,10 minRecoveryNo
7M59FlurbiprofenRectumT3N2M1IVFOLFOX x19, FOLFIRI x8, FOLFOX x102985SDConsciousness loss, respiratory distress, cold sweatingImmediateRecoveryNo
8M62NilSigmoid colonT3N1M1IVFOLFIRI + Bevacizumabx6, FOLFOX x7785PDConsciousness loss, respiratory distress, cold sweating20 minRecoveryNo
Literature review

Twenty-three relevant English-language studies, published from 1997-2011, regarding SAR following oxaliplatin-related chemotherapy were reported (Table 2). All studies were retrospective; few included the same patients. We found 59 reported cases that fitted the definition of life-threatening SAR from MEDLINE® and PubMed®[8-30]. Together with the 8 cases we presented, the median cycles of oxaliplatin given before SAR developed was 10 (range, 2-29). Most common symptoms were respiratory distress (60%), fever (55%), and hypotension (54%). Three fatal events were reported (4.5%). Eleven patients from these 66 cases were rechallenged with oxaliplatin.

Table 2 Studies on severe anaphylactic reactions following oxaliplatin, including data published from 1997 to 2012 in English (24 studies, n = 66).
Ref.Published year/regionPatient No.Age (yr)Male/femalePrevious oxaliplatin cyclesOxaliplatin dose (mg/m2)Presenting symptomsOnset time after oxaliplatin infusionOutcome
de Gramont et al[10]1997/France5NANANANANANARecovery
Tournigand et al[11]1998/France559-773/25-1285-100Reduced blood pressure, flushing, headache, tachycardia, respiratory distressImmediateRecovery
Larzillière et al[12]1999/France1551/0585Flushing, profuse sweats, arterial hypertension, tachycardia30 minRecovery
Médioni et al[13]1999/France1631/06100Visual disturbances, edema, tachycardia, severe hypotension, anaphylactic shockImmediateRecovery
Sørbye et al[14]2000/Norway140, 521/0885Severe thrombocytopeniaImmediateRecovery
Santini et al[15]2001/Italy1521/0660Chills, fever, nausea, vomiting, crampy abdominal pain, diarrhea, hypotension15 minRecovery
Schüll et al[16]2001/Austria1541/0585Flush, generalised erythema of the trunk, nausea, hypotension30 minRecovery
Brandi et al[17]2003/Italy9NANA2-17NADyspnea, laryngospasm, agitation, tachycardia, precordial pain, erythema, sweatingNARecovery
Thomas et al[18]2003/United States1500/19NAFever, respiratory distress2 hRecovery
Lenz et al[19]2003/Germany2NANANA85Severe abdominal, chest pain.ImmediateRecovery
Bhargava et al[20]2004/United States1500/112NAPalpitation, flushing, hypotensive, wheezing15 minRecovery
González-Mahave et al[21]2005/Spain243, 441/14, 11NARespiratory collapse, feverImmediateRecovery
Maindrault-Goebel et al[22]2005/France3NANANANAAnaphylactic shockNARecovery
Siu et al[8]2006/Hong Kong2NANANA100Hypotension, oxygen desaturatio, full-blown anaphylactic reactionsNANA
Tze et al[23]2006/China1600/112NAAnaphylactic shockImmediateRecovery
Lee et al[24]2006/Taiwan436-74NA6-785-100Anaphylactic shock, hypertensive crisis5-50 minRecovery
Yanqi et al[25]2007/China1521/06150 mgAnaphylactic shock10 minRecovery
Santodirocco et al[26]2008/Italy1440/11485Acute thrombocytopenia, hemolysis, bleeding1 hRecovery
Shao et al[27]2008/Taiwan1641/023NAThrombocytopenia1 hFatal
Chay et al[9]2010/Singapore1136-754/7NANARespiratory collapse, flushing, hypokalemiaNARecovery
Pietrantonio et al[28]2010/Italy1NANANANAAcute thrombocytopeniaNARecovery
Potenza et al[29]2010/Italy1461/0685Respiratory collapse10 hRecovery
Teng et al[30]2011/Taiwan1781/01785Pancytopenia, coagulopathy, intracranial hemorrhage30 minFatal
Wang et al, this study2012/Taiwan736-723/45-2985-90Consciousness loss, chest tightness, cold sweating, nausea, vomiting, shockimmediately to 2 h1 fatal
DISCUSSION

According to previous studies, the estimated incidence of oxaliplatin-induced SAR was less than 2%[10,17,18,24,31]. In 2007, Lee et al[24] reported the incidence of SAR as 1.32% (4 of 303 cases) in Taiwan. In our study, the incidence is 1.9% (8 of 412 cases). Multiple suggestions to reduce the incidence of adverse reactions have been proposed, including the use of various neuroprotective agents, in the hope of achieving adequate oxaliplatin doses with less neuropathy[5]. Much less is known about acute reactions such as anaphylaxis, but this is generally considered to be associated with immune-mediated effects, as evidenced by detection of drug-dependent IgG antibodies with or without complement[6,7]. Two independent pathogenetic mechanisms have been proposed for this toxicity. Some authors described the formation of autoantibodies to erythrocytes and, more rarely, to platelets and neutrophils as a result of oxaliplatin adsorption on blood cells[32]. By contrast, other authors reported high levels of cytokines [i.e., interleukin (IL) 6, IL10 and tumor necrosis factor-α] suggesting that oxaliplatin-dependent toxicity may be triggered by a massive release of pro-inflammatory molecules[33].

In literature reviews, SAR developed after several cycles of oxaliplatin chemotherapy (median cycles before SAR is 10), suggesting a sensitization process of type I hypersensitivity due to the rapid appearance of symptoms[22,34]. Based on Chay et al[9], females appeared more prone to severe oxaliplatin reactions for which the reason remains unclear, and all females manifested acute hypokalemia. Recently reported ex-vivo work suggests that oxaliplatin may interfere with voltage-gated potassium channels[35] and hypothesizes that axonal membrane hyperpolarization[36,37] may account for the observed hypokalemia, with potassium ion channel activation resulting in an intracellular influx of potassium. However, in our study there were no such findings including female predominance and hypokalemia after the episode.

Theoretically, prolongation of the infusion rate with premedication including steroids and antihistamines could be a method to prevent SAR after oxaliplatin use. We adopted this strategy before rechallenging oxaliplatin in patient 3. However, in 2001 Stahl et al[38] reported that allergic reactions to oxaliplatin may still occur after steroid prophylaxis. In 2006, Siu et al[8] reported premedications with steroid and chlorpheniramine seemed ineffective in preventing SAR. In 2011, Siu et al[39] developed a simple rechallenge protocol for mild hypersensitivity reactions, including intravenous dexamethasone, diphenhydramine and ranitidine, as well as prolongation of the oxaliplatin infusion time with a high success rate of 70%. Why did the anaphylactic reactions disappear after rechallenge of oxaliplatin in patient 3? A possible explanation for the disappearance of symptoms may be the much lower peak plasma concentrations of the platinum compound and its metabolites in case of a protracted infusion[3], thus resulting in a minor and/or delayed, clinically negligible cytokine release reaction. In literature reviews, five of eleven rechallenged patients could tolerate oxaliplatin with no or minimal discomfort. However, there were still three patients developing SAR after receiving prolonged infusion of oxaliplatin. There were also reported cases initially having only a mild hypersensitivity reaction to oxaliplatin, who developed SAR after rechallenge with prolonged infusion schedule[22]. Therefore, it seems that prolonged infusion of oxaliplatin or using a desensitization program could only benefit a few patients who developed SAR. So, changing the chemotherapy regimen might be a better choice.

The mortality rate of oxaliplatin-related SAR was 4.5% (3 of 66 patients). In 2008, Shao et al[27] reported a fatal thrombocytopenia with a large intracranial hemorrhage with brain herniation after oxaliplatin chemotherapy. In 2011, Teng et al[30] reported another fatal pancytopenia with intracranial hemorrhage after oxaliplatin treatment. In our study, the patient who died initially presented with anaphylactic shock and loss of consciousness immediately after oxaliplatin infusion. All these three patients had been heavily pretreated with oxaliplatin and had received 23, 17 and 13 cycles of oxaliplatin treatment, respectively. To counteract the underlying immune-mediated mechanism, the use of steroids seems to be one of the most cost-effective approaches, especially when the patient’s condition is life threatening[7,40]. This may also explain the fatalities in the patients reported by Shao et al[27], Teng et al[30] and our patient, who did not receive a steroid. Are there any predictors or risk factors for this rare but life-threatening event before oxaliplatin use? In 2011, Seki et al[41] reported a higher neutrophil count and lower monocyte count were two risk factors for grade 3/4 reactions in oxaliplatin-induced hypersensitivity reactions in Japanese patients. However, we didn’t observe such a relationship in our study and the literature review.

Target therapy with monoclonal antibodies, including bevacizumab, cetuximab, and panitumumab, can also result in SAR[42]. Up till April 2012, there have been 14  698 people reported to have side effects when taking bevacizumab. Among them, 87 people (0.59%) have SAR[43]. In our study, one patient (patient 4) developed SAR after bevacizumab and oxaliplatin infusion. In our hospital, bevacizumab was started first and infused over 1-h. Oxaliplatin was infused after bevacizumab infusion. This patient developed SAR about 3 h after bevacizumab infusion and 2 h after oxaliplatin infusion. It is very difficult to differentiate the cause of SAR in this patient. But due to the time of onset of SAR, it is reasonable to suspect oxaliplatin.

Our study does have several limitations. First, being a retrospective review, it is difficult to confirm now whether those observed reactions are genuine hypersensitivity reactions or whether they developed as a result of oxaliplatin infusion only, although the temporal relationship between infusion and onset of reaction is suggestive. Therefore, it is possible that the risk may have been overestimated. We can also argue the other way round, that is, some mild reactions may have been missed resulting in underestimation.

In conclusion, SAR is rare but serious, and must be considered in patients receiving oxaliplatin-related chemotherapy, especially in heavily pretreated patients. Physicians should be cautious when patients have repeated symptoms or signs of allergic reaction to oxaliplatin. At the moment, the mechanisms underlying oxaliplatin-related SAR remain uncertain. Prevention with prolongation of the infusion rate, steroid use and antihistamines are still in debate. Rechallenge with oxaliplatin is suggested only in carefully selected patients and should be used with caution. We recommend changing the chemotherapy regimen in patients experiencing oxaliplatin-induced SAR. Further extensive examinations with a large number of patients to determine the mechanism, the predictors, preventive methods and management strategy of oxaliplatin-induced SAR are recommended.

COMMENTS
Background

Oxaliplatin is a third generation platinum compound frequently used in the treatment of stage III and stage IV colorectal cancer. Among the side effects of this agent, hypersensitivity reaction and anaphylaxis refers to undesirable reactions produced by the normal immune system, including allergies and autoimmunity. These reactions may be damaging, uncomfortable, or occasionally fatal. The percentage of hypersensitivity reactions quoted in different studies ranges from 8% to 20%. The authors presented their experience in this retrospective study and conducted a systemic review.

Research frontiers

Much less is known about acute reactions such as anaphylaxis, but it is generally considered to be associated with immune-mediated effects, as evidenced by detection of drug-dependent IgG antibodies with or without complement. Further extensive examination with a large number of patients to determine the mechanism, the predictors, preventive methods and management strategy of oxaliplatin-induced severe anaphylactic reactions (SAR) are recommended.

Innovations and breakthroughs

Life-threatening SAR have been reported but no systemic review had been performed. Here, the authors performed a retrospective analysis of the patients who had been exposed to oxaliplatin and selected those who developed SAR requiring hospitalization with medical intervention and conducted a systemic literature review on this issue.

Applications

Physicians should be cautious when patients have repeated symptoms or signs of allergic reaction to oxaliplatin. The effectiveness of prevention with prolongation of the infusion rate, steroid use and antihistamines is still in debate. Rechallenge of oxaliplatin is suggested only in highly selected patients and should be used with caution. The authors recommend changing the chemotherapy regimen in patients experiencing oxaliplatin-induced SAR.

Peer review

This manuscript is a retrospective analysis of oxaliplatin chemotherapy-induced SAR at Kaohsiung Veterans General Hospital in Taiwan. In addition, the authors have conducted a literature review on the same issue. This side effect is rare but is a life-threatening event; the authors have made some recommendations on the use of oxaliplatin as chemotherapy. This is important information which needs to be reported.

Footnotes

Peer reviewers: Susumu Ohwada, Associate Professor, Department of Surgery, Gunma University Graduate School of Medicine, 3-39-15 Shoma-Machi, Maebashi 371-8511, Japan; Cuong D Tran, PhD, Research Fellow, Affiliate Lecturer, University of Adelaide, Gastroenterology Unit, Children, Youth and Women’s Health Service, 72 King William Rd, North Adelaide, SA 5006, Australia

S- Editor Shi ZF L- Editor O’Neill M E- Editor Zhang DN

References
1.  André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.  [PubMed]  [DOI]  [Cited in This Article: ]
2.  Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136-147.  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Culy CR, Clemett D, Wiseman LR. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs. 2000;60:895-924.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Saif MW. Hypersensitivity reactions associated with oxaliplatin. Expert Opin Drug Saf. 2006;5:687-694.  [PubMed]  [DOI]  [Cited in This Article: ]
5.  Grothey A, Hart LL, Rowland KM, Ansari RH, Alberts SR, Chowhan NM, Shpilsky A, Hochster HS. Intermittent oxaliplatin administration and time-to-treatment failure in metastatic colorectal cancer: Final results of the phase III CONcePT trial. J Clin Oncol. 2008;26:Abstract 4010 Available from: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34113.  [PubMed]  [DOI]  [Cited in This Article: ]
6.  James E, Podoltsev N, Salehi E, Curtis BR, Saif MW. Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect? Clin Colorectal Cancer. 2009;8:220-224.  [PubMed]  [DOI]  [Cited in This Article: ]
7.  Bautista MA, Stevens WT, Chen CS, Curtis BR, Aster RH, Hsueh CT. Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol. 2010;3:12.  [PubMed]  [DOI]  [Cited in This Article: ]
8.  Siu SW, Chan RT, Au GK. Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol. 2006;17:259-261.  [PubMed]  [DOI]  [Cited in This Article: ]
9.  Chay WY, Chew L, Yeoh TT, Tan MH. An association between transient hypokalemia and severe acute oxaliplatin-related toxicity predominantly in women. Acta Oncol. 2010;49:515-517.  [PubMed]  [DOI]  [Cited in This Article: ]
10.  de Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, Raymond E, Moreau S, Le Bail N, Krulik M. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 1997;33:214-219.  [PubMed]  [DOI]  [Cited in This Article: ]
11.  Tournigand C, Maindrault-Goebel F, Louvet C, de Gramont A, Krulik M. Severe anaphylactic reactions to oxaliplatin. Eur J Cancer. 1998;34:1297-1298.  [PubMed]  [DOI]  [Cited in This Article: ]
12.  Larzillière I, Brandissou S, Breton P, Lingoungou A, Gargot D, Ramain JP, Harnois C. Anaphylactic reaction to oxaliplatin: a case report. Am J Gastroenterol. 1999;94:3387-3388.  [PubMed]  [DOI]  [Cited in This Article: ]
13.  Médioni J, Coulon MA, Morere JF, Hennebelle F, Piperno-Neumann S, Breau JL. Anaphylaxis after oxaliplatin. Ann Oncol. 1999;10:610.  [PubMed]  [DOI]  [Cited in This Article: ]
14.  Sørbye H, Bruserud Y, Dahl O. Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and haemolysis. Acta Oncol. 2001;40:882-883.  [PubMed]  [DOI]  [Cited in This Article: ]
15.  Santini D, Tonini G, Salerno A, Vincenzi B, Patti G, Battistoni F, Dicuonzo G, Labianca R. Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol. 2001;12:132-133.  [PubMed]  [DOI]  [Cited in This Article: ]
16.  Schüll B, Kornek GV, Scheithauer W. Idiosyncratic reaction after oxaliplatin: circumvention by use of a continuous infusional administration schedule. Ann Oncol. 2001;12:1653-1654.  [PubMed]  [DOI]  [Cited in This Article: ]
17.  Brandi G, Pantaleo MA, Galli C, Falcone A, Antonuzzo A, Mordenti P, Di Marco MC, Biasco G. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer. 2003;89:477-481.  [PubMed]  [DOI]  [Cited in This Article: ]
18.  Thomas RR, Quinn MG, Schuler B, Grem JL. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer. 2003;97:2301-2307.  [PubMed]  [DOI]  [Cited in This Article: ]
19.  Lenz G, Hacker UT, Kern W, Schalhorn A, Hiddemann W. Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution. Anticancer Drugs. 2003;14:731-733.  [PubMed]  [DOI]  [Cited in This Article: ]
20.  Bhargava P, Gammon D, McCormick MJ. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer. 2004;100:211-212.  [PubMed]  [DOI]  [Cited in This Article: ]
21.  González-Mahave I, Lobera Iabairu T, Blasco Sarramián A, del Pozo Gil MD, Zorrilla M, Vélez de Mendizábal E. Anaphylaxis produced by oxaliplatin. J Investig Allergol Clin Immunol. 2005;15:75-77.  [PubMed]  [DOI]  [Cited in This Article: ]
22.  Maindrault-Goebel F, André T, Tournigand C, Louvet C, Perez-Staub N, Zeghib N, De Gramont A. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer. 2005;41:2262-2267.  [PubMed]  [DOI]  [Cited in This Article: ]
23.  Tze CNV. Anaphylactic shock to oxaliplatin in the adjuvant context. J Pharm Technol. 2006;22:221-225.  [PubMed]  [DOI]  [Cited in This Article: ]
24.  Lee MY, Yang MH, Liu JH, Yen CC, Lin PC, Teng HW, Wang WS, Chiou TJ, Chen PM. Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer. 2007;15:89-93.  [PubMed]  [DOI]  [Cited in This Article: ]
25.  Yanqi C. Anaphylactic shock attributed to oxaliplatin use. Adverse Drug React J. 2007;9:287.  [PubMed]  [DOI]  [Cited in This Article: ]
26.  Santodirocco M, Lombardi V, Fesce C, Palumbo G, Capalbo S, Landriscina M. Life-threatening oxaliplatin-induced acute thrombocytopenia, hemolysis and bleeding: a case report. Acta Oncol. 2008;47:1602-1604.  [PubMed]  [DOI]  [Cited in This Article: ]
27.  Shao YY, Hong RL. Fatal thrombocytopenia after oxaliplatin-based chemotherapy. Anticancer Res. 2008;28:3115-3117.  [PubMed]  [DOI]  [Cited in This Article: ]
28.  Pietrantonio F, Di Bartolomeo M, Buzzoni R, Bajetta E. Acute immune-mediated thrombocytopenia due to oxaliplatin administration: a case report. Tumori. 2010;96:154-156.  [PubMed]  [DOI]  [Cited in This Article: ]
29.  Potenza S, Nasti G, Ottaiano A, Filippelli A, Rossi F, Capuano A. Severe respiratory symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction. Invest New Drugs. 2010;28:185-186.  [PubMed]  [DOI]  [Cited in This Article: ]
30.  Teng CJ, Hsieh YY, Chen KW, Chao TC, Tzeng CH, Wang WS. Sudden-onset pancytopenia with intracranial hemorrhage after oxaliplatin treatment: a case report and literature review. Jpn J Clin Oncol. 2011;41:125-129.  [PubMed]  [DOI]  [Cited in This Article: ]
31.  Misset JL. Oxaliplatin in practice. Br J Cancer. 1998;77 Suppl 4:4-7.  [PubMed]  [DOI]  [Cited in This Article: ]
32.  Curtis BR, Kaliszewski J, Marques MB, Saif MW, Nabelle L, Blank J, McFarland JG, Aster RH. Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol. 2006;81:193-198.  [PubMed]  [DOI]  [Cited in This Article: ]
33.  Koutras AK, Makatsoris T, Paliogianni F, Kopsida G, Onyenadum A, Gogos CA, Mouzaki A, Kalofonos HP. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology. 2004;67:179-182.  [PubMed]  [DOI]  [Cited in This Article: ]
34.  Watts SW. 5-HT in systemic hypertension: foe, friend or fantasy? Clin Sci (Lond). 2005;108:399-412.  [PubMed]  [DOI]  [Cited in This Article: ]
35.  Kagiava A, Tsingotjidou A, Emmanouilides C, Theophilidis G. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology. 2008;29:1100-1106.  [PubMed]  [DOI]  [Cited in This Article: ]
36.  Tan MH, Chay WY, Ng JH, Teh BT, Chew L. Transient bilateral abducens neuropathy with post-tetanic facilitation and acute hypokalemia associated with oxaliplatin: a case report. J Med Case Rep. 2010;4:36.  [PubMed]  [DOI]  [Cited in This Article: ]
37.  Kuwabara S, Kanai K, Sung JY, Ogawara K, Hattori T, Burke D, Bostock H. Axonal hyperpolarization associated with acute hypokalemia: multiple excitability measurements as indicators of the membrane potential of human axons. Muscle Nerve. 2002;26:283-287.  [PubMed]  [DOI]  [Cited in This Article: ]
38.  Stahl M, Köster W, Wilke H. Reaction after oxaliplatin--prevention with corticosteroids? Ann Oncol. 2001;12:874.  [PubMed]  [DOI]  [Cited in This Article: ]
39.  Siu SW, Chan WL, Liu KY, Choy TS, Leung TW, Au KH. Re-challenging patients with oxaliplatin allergy: the successful use of a standardised pre-medication protocol in a single institute. Clin Oncol (. R Coll Radiol). 2011;23:558-559.  [PubMed]  [DOI]  [Cited in This Article: ]
40.  Fontão-Wendel R, Hoff PM, Lazar A, Freitas D, Novis Y, Patah P, Tsujita M, Balthazar A, Pierroti M, Wendel S. Immune-mediated pancytopenia induced by oxaliplatin: a case report. Transfusion. 2010;50:1453-1459.  [PubMed]  [DOI]  [Cited in This Article: ]
41.  Seki K, Senzaki K, Tsuduki Y, Ioroi T, Fujii M, Yamauchi H, Shiraishi Y, Nakata I, Nishiguchi K, Matsubayashi T. Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci. 2011;8:210-215.  [PubMed]  [DOI]  [Cited in This Article: ]
42.  Schwartzberg LS, Stepanski EJ, Fortner BV, Houts AC. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer. 2008;16:393-398.  [PubMed]  [DOI]  [Cited in This Article: ]
43.   Available from: http: //www.ehealthme.com/ds/avastin/anaphylactic shock..  [PubMed]  [DOI]  [Cited in This Article: ]